A New Treatment That Can Be Taken at Home for Myelodysplastic Syndrome Receives FDA Approval

Decitabine and cedazuridine (Inqovi) tablets received US Food and Drug Administration (FDA) approval on 7 July 2020 for the treatment of adult patients with myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). This represents an important advance in treatment options for patients with MDS, a type of blood cancer, who previously had to visit a healthcare facility to receive intravenous treatment (through a vein).
The ASTX727-01-B Trial
The approval is based on clinical trial results showing similar drug concentrations with intravenous decitabine and Inqovi. In addition, approximately half of the patients who had previously been transfusion-dependent were able to go without a transfusion over an 8-week period.
Inqovi's safety profile was also similar to that of intravenous decitabine. Some common side effects of Inqovi include fatigue, constipation, bleeding, muscle pain, mucositis (mouth sores), arthralgia (joint pain), nausea, and fever with a low white blood cell count.
Inqovi can cause fetal harm (harm to an unborn baby), and male and female patients of reproductive age are advised to use effective contraception (birth control). Inqovi is taken orally as one tablet once daily on the first 5 days of each 28-day cycle.
Sources
fda.gov - 7 July 2020
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.